Name | Title | Contact Details |
---|
ChoiceSpine, LP was founded in December of 2006 in Knoxville, TN. The company is designed to take to the market technically-superior spinal products through a service-focused distribution network. The management team of ChoiceSpine has more than 70 years of industry experience in the areas of research and development, engineering and manufacturing, distribution and sales, financial management and administration. Rick Henson and Marty Altshuler are co-founders and executives of the corporation. They have extensive knowledge of the orthopedic and spinal markets. They are co-principals of ChoiceSpine. They have worked together for 20 years in creating successful healthcare businesses. ChoiceSpine acquired Orthotec, a 40 million dollar company, and now holds the exclusive rights for the U.S. market, several patents and 6 specific spinal conditions. These innovative and proprietary products, when combined with effective procedures, have a successful track record of producing better quality outcomes in surgical patients.
bioTheranostics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Heartsine Technologies is a Newtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marus Dental International is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LENSAR, Inc. is a global leader in next-generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and efficiency while optimizing overall visual outcomes. LENSAR`s proprietary Augmented Reality technology -- reconstructed 3-D imaging, measurement, and guidance system -- offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery, and efficient lens fragmentation that can reduce, and potentially eliminate phaco energy. The LENSAR Laser System also offers the industry`s smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms. The LENSAR Laser System has been cleared by FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only